Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 9
States / cities: Fountain Valley, California • Los Angeles, California • Lakeland, Florida + 6 more

Conditions: Uveal Melanoma, Radiation Retinopathy, Radiation Maculopathy
Interventions: Ranibizumab; Drug
Lead sponsor: Shields, Shields and Associates; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid Use, Shoulder Osteoarthritis, Avascular Necrosis, Rotator Cuff Tear, Arthritis;Inflammatory
Interventions: Gabapentin, Celecoxib, toradol, acetaminophen, regional block, propofol, IV lidocaine, rocuronium, vecuronium, sevoflurane, desflurane; Drug
Lead sponsor: OrthoCarolina Research Institute, Inc.; Other
Eligibility: 50 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Diabetes Mellitus, Diet
Interventions: LoBAG30 diet, Control Diet; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cytomegalovirus Infections
Interventions: Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution); Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
Interventions: App, Usual Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fractures
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Ohio Orthopedic Center of Excellence; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Upper Arlington, Ohio

Conditions: Hemophilia A With Inhibitor
Interventions: Eloctate ITI, Emicizumab; Drug
Lead sponsor: Margaret Ragni; Other
Eligibility: Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Cesarean Section, Misoprostol, Oxytocin, High Risk Pregnancy
Interventions: Oxytocin, Misoprostol; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gut Health, Gastrointestinal Symptoms, Safety in Healthy Adults
Interventions: IgG Binding Protein LT, Placebo; Dietary Supplement
Lead sponsor: Bactolife A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions: Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High; Drug
Lead sponsor: ARKAY Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Albany, New York

Conditions: Burns
Interventions: bacitracin/xeroform, Polymem; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sepsis, Burn, Inflammation, Burn Infection
Interventions: PSP Monitoring; Device
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 and Gardasil, rLP2086, Gardasil; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 2,499 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 87
States / cities: Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Peripheral Artery Disease
Interventions: vonapanitase, Placebo; Drug
Lead sponsor: Proteon Therapeutics; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Long Beach, California • Denver, Colorado • Gainesville, Florida + 5 more

Conditions: Pediatric Obesity
Interventions: CHAMP+; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 1,943 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cesarean Section Complications, Wound Breakdown, Wound Infection, Satisfaction, Surgical Wound Infection
Interventions: ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG), Standard Wound Care; Combination Product · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Asthma
Interventions: Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Riverside, California • Roseville, California + 10 more

Conditions: Low Back Pain, Pain
Interventions: D-cycloserine, placebo; Drug
Lead sponsor: Thomas J. Schnitzer; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson Disease
Interventions: Low dose levodopa, High dose levodopa; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vision, Low, Blindness
Interventions: Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces, Biomechanical Measurements, Psychophysical Tasks; Diagnostic Test · Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Interventions: Enteral Nutrition; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Ischemia Reperfusion Injury
Interventions: recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Opioid-Free Shoulder Arthroplasty

LoBAG30 Diet in Patients on Metformin

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Psychosocial Mobile App for Chronic Graft-Versus-Host Disease

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

The Hemophilia Inhibitor Eradication Trial

Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions

IgG Binding Protein LT in Support of a Healthy Gut on the Go

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds

Sepsis Biomarker Monitoring in Burn Patients

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Building Blocks for Healthy Preschoolers

Antimicrobial Dressing Versus Standard Dressing in Obese Women Undergoing Cesarean Delivery

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

D-cycloserine in the Management of Chronic Low Back Pain

Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease

Validation of Texture Changing Coatings for Use in At-Home Rapid Tests

Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation